ALDH2 Enzyme Deficiency in Diabetic Cardiomyopathy.

Area of Science:

• Cardiology
• Genetics
• Biochemistry

Background:

• Diabetic cardiomyopathy (DCM) is a serious diabetes complication, prevalent in East Asian populations.
• The ALDH2*2 genetic variant impairs aldehyde detoxification, increasing cardiac damage via oxidative stress and inflammation.

Purpose of the Study:

• To review the pathological role of ALDH2 deficiency in DCM.
• To integrate clinical data with mechanistic insights and evaluate therapies for susceptible populations.

Main Methods:

• Systematic review integrating clinical observations.
• Analysis of in vitro and in vivo experimental models.
• Evaluation of emerging therapeutic strategies.

Main Results:

• ALDH2*2 exacerbates oxidative stress and mitochondrial dysfunction in hyperglycemia, leading to cardiac fibrosis and functional decline.
• ALDH2*2 carriers exhibit increased susceptibility to metabolic stress, worsening DCM.
• ALDH2 activators (e.g., Alda-1) and SGLT2 inhibitors (e.g., empagliflozin) show therapeutic potential.

Conclusions:

• ALDH2 deficiency significantly contributes to DCM, particularly in East Asian populations.
• Targeted therapies can mitigate cardiac damage by reducing oxidative stress and improving mitochondrial function.
• Further clinical trials are needed to validate these treatments for ALDH2-deficient individuals.